Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

H. van Cruijsen, E.E. Voest, C.J.A. Punt, K. Hoekman, P.O. Witteveen, M.R. Meijerink, T.A. Puchalski, J. Robertson, O. Saunders, J.M. Jurgensmeier, C.M.L. van Herpen, G. Giaccone

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)901-911
JournalEuropean Journal of Cancer
Issue number5
Publication statusPublished - 2010

Cite this